JPWO2020115548A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020115548A5 JPWO2020115548A5 JP2021531486A JP2021531486A JPWO2020115548A5 JP WO2020115548 A5 JPWO2020115548 A5 JP WO2020115548A5 JP 2021531486 A JP2021531486 A JP 2021531486A JP 2021531486 A JP2021531486 A JP 2021531486A JP WO2020115548 A5 JPWO2020115548 A5 JP WO2020115548A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- mammal
- inhibitor
- administered
- ddri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 38
- 241000124008 Mammalia Species 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 239000003112 inhibitor Substances 0.000 claims description 24
- 229940051022 radioimmunoconjugate Drugs 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 239000012661 PARP inhibitor Substances 0.000 claims description 10
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 150000003384 small molecules Chemical group 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims description 8
- 150000004696 coordination complex Chemical class 0.000 claims description 6
- 230000028617 response to DNA damage stimulus Effects 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 229940125774 BAY 1895344 Drugs 0.000 claims description 4
- YBXRSCXGRPSTMW-CYBMUJFWSA-N C[C@@H]1COCCN1C1=CC(C2=CC=NN2C)=C2C=CN=C(C3=CC=NN3)C2=N1 Chemical compound C[C@@H]1COCCN1C1=CC(C2=CC=NN2C)=C2C=CN=C(C3=CC=NN3)C2=N1 YBXRSCXGRPSTMW-CYBMUJFWSA-N 0.000 claims description 4
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 4
- 229960000572 olaparib Drugs 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 3
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 claims description 2
- SCGCBAAYLFTIJU-CQSZACIVSA-N (3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)-4-pyrimidinyl]-3-methylmorpholine Chemical group C[C@@H]1COCCN1C1=CC(C2(CC2)S(C)(=O)=O)=NC(C=2C=3C=CNC=3C=CC=2)=N1 SCGCBAAYLFTIJU-CQSZACIVSA-N 0.000 claims description 2
- VQSZIPCGAGVRRP-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]quinolin-2-one Chemical compound FC=1C(=CC=2C3=C(C=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)OCCCN1CCCCC1 VQSZIPCGAGVRRP-UHFFFAOYSA-N 0.000 claims description 2
- AOTRIQLYUAFVSC-UHFFFAOYSA-N 8-[6-[3-(dimethylamino)propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=N1)C1=CC=2C3=C(C=NC2C=C1)N(C(N3C3CCOCC3)=O)C)C AOTRIQLYUAFVSC-UHFFFAOYSA-N 0.000 claims description 2
- 229940127011 AZD1390 Drugs 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 102100038083 Endosialin Human genes 0.000 claims description 2
- 101710144543 Endosialin Proteins 0.000 claims description 2
- 101000740462 Escherichia coli Beta-lactamase TEM Proteins 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 102100023037 Wee1-like protein kinase Human genes 0.000 claims description 2
- 229940125666 actinium-225 Drugs 0.000 claims description 2
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical compound [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 claims description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 2
- RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 claims description 2
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 claims description 2
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 claims description 2
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 claims description 2
- 101150113535 chek1 gene Proteins 0.000 claims description 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 2
- 229950011068 niraparib Drugs 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 229950007072 pamiparib Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 108060006633 protein kinase Proteins 0.000 claims description 2
- 229960005562 radium-223 Drugs 0.000 claims description 2
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 claims description 2
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229950004707 rucaparib Drugs 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 229950004550 talazoparib Drugs 0.000 claims description 2
- GZCRRIHWUXGPOV-CBESVEIWSA-N terbium-149 Chemical compound [149Tb] GZCRRIHWUXGPOV-CBESVEIWSA-N 0.000 claims description 2
- ZSLUVFAKFWKJRC-FTXFMUIASA-N thorium-227 Chemical compound [227Th] ZSLUVFAKFWKJRC-FTXFMUIASA-N 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 229950011257 veliparib Drugs 0.000 claims description 2
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193520A JP2025013486A (ja) | 2018-12-03 | 2024-11-05 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774847P | 2018-12-03 | 2018-12-03 | |
| US62/774,847 | 2018-12-03 | ||
| PCT/IB2019/001292 WO2020115548A1 (en) | 2018-12-03 | 2019-12-03 | Radioimmunoconjugates and dna damage and repair inhibitor combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193520A Division JP2025013486A (ja) | 2018-12-03 | 2024-11-05 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022511471A JP2022511471A (ja) | 2022-01-31 |
| JP2022511471A5 JP2022511471A5 (https=) | 2022-12-12 |
| JPWO2020115548A5 true JPWO2020115548A5 (https=) | 2022-12-12 |
Family
ID=70973593
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531492A Pending JP2022513700A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とチェックポイント阻害剤の併用療法 |
| JP2021531486A Pending JP2022511471A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
| JP2024193520A Pending JP2025013486A (ja) | 2018-12-03 | 2024-11-05 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531492A Pending JP2022513700A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とチェックポイント阻害剤の併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193520A Pending JP2025013486A (ja) | 2018-12-03 | 2024-11-05 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20220088231A1 (https=) |
| EP (2) | EP3890789A4 (https=) |
| JP (3) | JP2022513700A (https=) |
| KR (2) | KR20210099073A (https=) |
| CN (4) | CN117482261A (https=) |
| AU (2) | AU2019394888A1 (https=) |
| BR (2) | BR112021010670A2 (https=) |
| CA (2) | CA3119917A1 (https=) |
| CL (2) | CL2021001432A1 (https=) |
| EA (2) | EA202191556A1 (https=) |
| IL (2) | IL283613A (https=) |
| MA (2) | MA54401A (https=) |
| MX (2) | MX2021006408A (https=) |
| PE (2) | PE20211286A1 (https=) |
| PH (2) | PH12021551282A1 (https=) |
| SG (2) | SG11202105112RA (https=) |
| WO (2) | WO2020115548A1 (https=) |
| ZA (1) | ZA202103429B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020142583A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| CR20210556A (es) | 2019-05-10 | 2021-12-17 | Janssen Biotech Inc | Quelantes macrocíclicos y métodos de uso de estos |
| WO2021142231A1 (en) * | 2020-01-10 | 2021-07-15 | Fusion Pharmaceuticals Inc. | Sustained immunotherapy |
| WO2021207086A1 (en) * | 2020-04-06 | 2021-10-14 | Fusion Pharmaceuticals Inc. | Tem-1-targeted radioimmunoconjugates and uses thereof |
| CN119792512A (zh) | 2020-10-14 | 2025-04-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| US20250275946A1 (en) * | 2021-02-02 | 2025-09-04 | Unm Rainforest Innovations | Combination therapy for the treatment of cancer |
| US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
| TW202320850A (zh) | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| US20250339571A1 (en) * | 2021-08-27 | 2025-11-06 | Actinium Pharmaceuticals, Inc. | Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer |
| CA3233733A1 (en) * | 2021-09-29 | 2023-04-06 | National Research Council Of Canada | Egfrviii-targeted compounds and uses thereof |
| TW202325344A (zh) * | 2021-11-02 | 2023-07-01 | 加拿大商融合製藥公司 | 治療癌症之方法 |
| CA3249955A1 (en) * | 2022-01-28 | 2023-08-03 | Fusion Pharmaceuticals Inc. | Polytherapy based on radiopharmaceuticals targeting NTSR1 and DNA damage response inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5053503A (en) * | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US7736651B1 (en) * | 2000-11-24 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Alpha emitting constructs and uses thereof |
| ES2408704T3 (es) * | 2005-01-05 | 2013-06-21 | Biogen Idec Ma Inc. | Moléculas de unión a Cripto |
| US7612178B2 (en) * | 2006-03-28 | 2009-11-03 | Biogen Idec Ma Inc | Anti-IGF-1R antibodies and uses thereof |
| WO2011060233A1 (en) * | 2009-11-11 | 2011-05-19 | The Trustees Of The University Of Pennsylvania | Anti-tem1 antibodies and uses thereof |
| ES2978177T3 (es) * | 2009-12-02 | 2024-09-06 | Immunomedics Inc | Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer |
| GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| SI3134127T1 (sl) * | 2014-04-25 | 2020-06-30 | Rinat Neuroscience Corp. | Konjugati zdravil s protitelesi z visoko stopnjo zdravila |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| EP3280439A1 (en) * | 2015-04-07 | 2018-02-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Anti-pd-l1 immunotoxin for use in therapy |
| US10702526B2 (en) * | 2015-04-20 | 2020-07-07 | Effector Therapeutics Inc. | Inhibitors of immune checkpoint modulators and related methods |
| WO2016172249A1 (en) * | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| EP3303398A1 (en) * | 2015-05-29 | 2018-04-11 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
| ES2875747T3 (es) * | 2016-01-11 | 2021-11-11 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia |
| EP3202788A1 (en) | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Endosialin-binding antibody |
| TWI755395B (zh) * | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| US11633506B2 (en) * | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
| EP3496707A4 (en) | 2016-08-09 | 2020-03-25 | Angimmune, LLC | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| WO2018038680A1 (en) * | 2016-08-24 | 2018-03-01 | Scinopharm Taiwan, Ltd. | Processes for preparing olaparib |
| KR20190053909A (ko) * | 2016-09-16 | 2019-05-20 | 바이오노믹스 리미티드 | 항체와 체크포인트 면역 억제제의 병용 요법 |
| BR112019011794A2 (pt) * | 2016-12-12 | 2019-10-29 | Daiichi Sankyo Co Ltd | composição farmacêutica, e, método terapêutico. |
| EP3585436A1 (en) * | 2017-02-24 | 2020-01-01 | Bayer AS | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| KR102612882B1 (ko) * | 2017-05-05 | 2023-12-11 | 센터 포 프로브 디벨롭먼트 앤드 커머셜리제이션 | 이관능성 킬레이트 및 그의 용도의 약동학적 증진 |
| CA3062538A1 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| US10093741B1 (en) * | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| JP2020533002A (ja) * | 2017-09-13 | 2020-11-19 | ラディミューン セラピュティックス， インク．Ｒａｄｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | メラニン抗体及びその使用 |
| CN111372613A (zh) * | 2017-11-22 | 2020-07-03 | 诺帝克纳诺维科特公司 | 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤 |
| CA3130747A1 (en) * | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
-
2019
- 2019-12-03 EA EA202191556A patent/EA202191556A1/ru unknown
- 2019-12-03 US US16/619,433 patent/US20220088231A1/en active Pending
- 2019-12-03 MX MX2021006408A patent/MX2021006408A/es unknown
- 2019-12-03 SG SG11202105112RA patent/SG11202105112RA/en unknown
- 2019-12-03 MX MX2021006407A patent/MX2021006407A/es unknown
- 2019-12-03 CN CN202311139310.7A patent/CN117482261A/zh active Pending
- 2019-12-03 CN CN202510572446.XA patent/CN120393061A/zh active Pending
- 2019-12-03 AU AU2019394888A patent/AU2019394888A1/en active Pending
- 2019-12-03 PE PE2021000815A patent/PE20211286A1/es unknown
- 2019-12-03 MA MA054401A patent/MA54401A/fr unknown
- 2019-12-03 EP EP19892173.6A patent/EP3890789A4/en active Pending
- 2019-12-03 JP JP2021531492A patent/JP2022513700A/ja active Pending
- 2019-12-03 BR BR112021010670-7A patent/BR112021010670A2/pt unknown
- 2019-12-03 CN CN201980079758.XA patent/CN113474014A/zh active Pending
- 2019-12-03 CA CA3119917A patent/CA3119917A1/en active Pending
- 2019-12-03 BR BR112021010799-1A patent/BR112021010799A2/pt not_active Application Discontinuation
- 2019-12-03 PE PE2021000808A patent/PE20211961A1/es unknown
- 2019-12-03 SG SG11202105192WA patent/SG11202105192WA/en unknown
- 2019-12-03 EA EA202191557A patent/EA202191557A1/ru unknown
- 2019-12-03 KR KR1020217020517A patent/KR20210099073A/ko not_active Ceased
- 2019-12-03 KR KR1020217020519A patent/KR20210099074A/ko not_active Ceased
- 2019-12-03 WO PCT/IB2019/001292 patent/WO2020115548A1/en not_active Ceased
- 2019-12-03 CA CA3119915A patent/CA3119915A1/en active Pending
- 2019-12-03 MA MA054399A patent/MA54399A/fr unknown
- 2019-12-03 WO PCT/IB2019/001342 patent/WO2020115556A1/en not_active Ceased
- 2019-12-03 AU AU2019393257A patent/AU2019393257A1/en active Pending
- 2019-12-03 US US16/619,432 patent/US11446401B2/en active Active
- 2019-12-03 JP JP2021531486A patent/JP2022511471A/ja active Pending
- 2019-12-03 CN CN201980079705.8A patent/CN113164632A/zh active Pending
- 2019-12-03 EP EP19893184.2A patent/EP3890790A4/en active Pending
-
2021
- 2021-05-20 ZA ZA2021/03429A patent/ZA202103429B/en unknown
- 2021-05-28 PH PH12021551282A patent/PH12021551282A1/en unknown
- 2021-05-28 PH PH12021551237A patent/PH12021551237A1/en unknown
- 2021-06-01 CL CL2021001432A patent/CL2021001432A1/es unknown
- 2021-06-01 CL CL2021001433A patent/CL2021001433A1/es unknown
- 2021-06-01 IL IL283613A patent/IL283613A/en unknown
- 2021-06-01 IL IL283598A patent/IL283598A/en unknown
- 2021-06-02 US US17/337,357 patent/US20210290789A1/en active Pending
- 2021-06-02 US US17/337,358 patent/US20210290788A1/en active Pending
-
2022
- 2022-08-15 US US17/819,911 patent/US20230270895A1/en not_active Abandoned
-
2024
- 2024-11-05 JP JP2024193520A patent/JP2025013486A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Poty et al. | α-emitters for radiotherapy: from basic radiochemistry to clinical studies—part 2 | |
| Costantini et al. | Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron–emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate | |
| Lin et al. | Peptide binder to glypican-3 as a theranostic agent for hepatocellular carcinoma | |
| Milenic et al. | Targeting of HER2 antigen for the treatment of disseminated peritoneal disease | |
| JPWO2020115548A5 (https=) | ||
| Milenic et al. | Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease | |
| Navarro-Teulon et al. | General overview of radioimmunotherapy of solid tumors | |
| Herbertson et al. | Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine | |
| Gestin et al. | Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies | |
| Lawal et al. | Advances in Radioligand Theranostics in Oncology: IO Lawal et al. | |
| DeNardo | Radioimmunodetection and therapy of breast cancer | |
| Supiot et al. | Comparison of the biologic effects of MA5 and B‐B4 monoclonal antibody labeled with iodine‐131 and bismuth‐213 on multiple myeloma | |
| Lin et al. | The evolution of antibodies into versatile tumor-targeting agents | |
| Levene et al. | Therapeutic monoclonal antibodies in oncology | |
| Goel et al. | Single-dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs | |
| Giugliano et al. | Radioligand therapy in metastatic breast cancer: harnessing precision oncology | |
| JPWO2020115556A5 (https=) | ||
| US9289519B2 (en) | Alpha emitting constructs and uses thereof | |
| Chatal et al. | Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors | |
| Zacchetti et al. | Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5. 3 in a mouse model for ovarian cancer | |
| Rinne et al. | 225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer | |
| Hull et al. | In vitro characterisation of [177Lu] Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer | |
| Sahlin et al. | Radioimmunotherapy—a potential novel tool for pancreatic cancer therapy? | |
| CA2547435A1 (en) | Targeting of erb antigens | |
| EP1091757B1 (en) | Alpha emitting constructs and uses thereof |